Possesses immunomodularity and antiangiogenic properties. Full Mechanism of action unknown. Structurally similar to thalidomide.

Recommended starting dose is 10mg daily by mouth with dose reductions for thrombocytopenia and neutropenia.

Treatment of patients with transfusion-dependent anemia due to MDS (myelodysplastic syndromes) associated with deletion of chromosome 5q. Also indicated for use in combination with dexamethasone in patients with multiple myeloma who have received one prior therapy.

Approved for use in combination with dexamethasone in patients with multiple myeloma who have received one prior therapy.

Neutropenia and thrombocytopenia requiring dose interruptions or reduction, DVT, PE, diarrhea, pruritis, fatigue.

There is insufficient information regarding teratogenic properties. It must be considered a potential teratogen because of its structural similarities to thalidomide.

Oral Medication

Patient education available through Celgene emphasizes effective contraception for 4 weeks for all patients and 2 negative pregnancy tests for women prior to starting treatment. Pregnancy tests are continued weekly × 4 weeks with start of treatment and at end of treatment.

May require blood product support and/or growth factors.